Results 1 to 10 of about 6,010 (179)

Cardiovascular Effect of Epoprostenol and Intravenous Cardiac Drugs for Acute Heart Failure on Canine Pulmonary Hypertension

Veterinary Sciences, 2023
Pulmonary hypertension (PH) is a life-threatening complication in dogs with cardiopulmonary disease. Epoprostenol is an intravenous pulmonary vasodilator used to treat PH in humans; however, its efficacy in dogs remains unknown.
Yunosuke Yuchi, Ryohei Suzuki, Shuji Satomi, Takahiro Saito, Takahiro Teshima, Hirotaka Matsumoto   +5 more
doaj   +2 more sources

An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report

Frontiers in Pediatrics, 2022
Idiopathic pulmonary arterial hypertension (PAH) is a rare, progressive disease affecting the pulmonary arteries. Epoprostenol, a synthetic prostaglandin analog, is the most potent pharmacological treatment modality used in patients with PAH. However, it
Ayako Chida-Nagai, Takao Tsujioka, Daisuke Sasaki, Gaku Izumi, Hirokuni Yamazawa, Atsuhito Takeda   +5 more
doaj   +2 more sources

Rapid initiation of intravenous epoprostenol infusion is the favored option in patients with advanced pulmonary arterial hypertension. [PDF]

PLoS ONE, 2015
Intravenous infusion (IVI) of epoprostenol is an effective treatment for patients with advanced pulmonary arterial hypertension (PAH). However, there is no widely accepted standard method for initiating the IVI therapy.
Mai Kimura, Yuichi Tamura, Makoto Takei, Tsunehisa Yamamoto, Tomohiko Ono, Masataka Kuwana, Keiichi Fukuda, Toru Satoh   +7 more
doaj   +2 more sources

Epoprostenol as an alternative anticoagulant for pediatric aquadex therapy: a safe and feasible option [PDF]

Frontiers in Pediatrics
BackgroundThe Aquadex ultrafiltration system offers a low extracorporeal volume option for the pediatric population. To maintain circuit patency, it relies on conventional anticoagulation, and data on alternative anticoagulation strategies are limited ...
Buria Naeem, Jenna Harper, Coleen McSteen, Dana Y. Fuhrman, Dana Y. Fuhrman   +4 more
doaj   +2 more sources

A Case of IgG4‐Related Disease Developing During Long‐Term High‐Dose Intravenous Epoprostenol Therapy in a Patient With Idiopathic Pulmonary Arterial Hypertension [PDF]

Pulmonary Circulation
Long‐term intravenous (IV) epoprostenol is a key therapy for pulmonary arterial hypertension (PAH); however, rare immune‐mediated conditions occurring during therapy remain incompletely characterised.
Takashi Inao, Kazuhiko Nakayama, Shintaro Yasui, Nanami Shite, Eriko Shiraki, Chiho Ohbayashi, Kojiro Otsuka, Hiroyuki Onishi, Soichiro Ohta, Masanori Iwahashi   +9 more
doaj   +2 more sources

Comparative efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension: a systematic review and network meta-analysis [PDF]

Frontiers in Medicine
BackgroundPulmonary arterial hypertension (PAH) is a progressive, fatal cardiopulmonary disorder characterized by elevated pulmonary vascular resistance leading to right heart failure.
Khaled M. Saleh, Jihad Mallat, Jihad Mallat, Samiuddin Mohammed, Govinda Bodi, Hosam Alazazzi, Simi Salim, Mohamed Elhennawi, Talha Iqbal, Hani Sabbour, Hani Sabbour   +10 more
doaj   +2 more sources

Real-World Experience of Midodrine in Hospital Setting in Pulmonary Arterial Hypertension [PDF]

CHEST Pulmonary
Background: Pulmonary arterial hypertension (PAH), a progressive disease, is characterized by increased pulmonary vascular resistance (PVR) and leads to right ventricular failure and premature death.
Noah Giese, MD, Zeenat Safdar, MD, MS, Anisha Mulumudi, BA, Sarah Momin, MD, Nelson Villasmil Hernandez, MD, Duc T. Nguyen, MD, PhD, Edward A. Graviss, PhD, MPH, FIDSA   +6 more
doaj   +2 more sources

How a Most Unlikely Drug Changed the Outcome of Pulmonary Arterial Hypertension [PDF]

Pulmonary Circulation
Epoprostenol is a prostaglandin that was first identified by investigators in 1976 and found to be a potent vasodilator and inhibiter of platelet aggregation, initially in animal studies and subsequently in humans. Based on these properties epoprostenol,
Ivan M. Robbins, Anna R. Hemnes
doaj   +2 more sources

Case report: High-dose epoprostenol therapy in pediatric patients with pulmonary hypertension and developmental lung disease

Frontiers in Pediatrics, 2023
Pulmonary hypertension (PH) with developmental lung disease is a life-threatening disease and accounts for 10%–12% of pediatric PH patients. Administration of specific pulmonary vasodilators to pediatric PH patients has brought about improvement of their
Yoshie Fukasawa, Hidenori Yamamoto, Miharu Ito, Miharu Ito, Akiko Saito, Akiko Saito, Kiyotaka Go, Yoshihito Morimoto, Kazushi Yasuda, Yoshiaki Sato, Masahiro Hayakawa, Taichi Kato   +11 more
doaj   +1 more source

Use of Aerosolized Prostacyclins in Critically Ill Patients and Association With Clinical Outcomes

Critical Care Explorations, 2023
IMPORTANCE:. Aerosolized prostacyclins are frequently used in patients with severe acute respiratory distress syndrome and refractory hypoxia. Previous studies have shown improvement in oxygenation with use of pulmonary vasodilators such as iloprost and ...
S. Talal Hussain, MD, Huzaifa A. Jaliawala, MD, Daniel Zhao, PhD, Sardar Hassan Ijaz, MD, Janice Tsui, PharmD, BCPS, Bobby Chasteen, RRT, Brent R. Brown, MD, Roberto J. Bernardo, MD, MS   +7 more
doaj   +1 more source